Evidence map›Paper›PMID 34233476›Full record

ArticleArteriosclerosis, thrombosis, and vascular biology2021

Genome-Wide Association Study Identifies a Functional

Paola León-Mimila, Hugo Villamil-Ramírez, Luis R Macías-Kauffer, Leonor Jacobo-Albavera, Blanca E López-Contreras, Rosalinda Posadas-Sánchez, Carlos Posadas-Romero, Sandra Romero-Hidalgo, Sofía Morán-Ramos, Mayra Domínguez-Pérez and 26 more

Open access · bronzeAbstract readMulticenter StudyVideo-Audio Media
In one paragraph

Article in Arteriosclerosis, thrombosis, and vascular biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Interaction betweenNutrients · 2023
    Article
  10. Article
  11. The Role of High-Density Lipoprotein Cholesterol in 2022.Current atherosclerosis reports · 2022
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors at 14 institutions in 7 countries.

Paola León-Mimila *Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Hugo Villamil-Ramírez *Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Luis R Macías-Kauffer *Unidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Leonor Jacobo-Albavera *Laboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City (L.J.-A., M.D.-P., T.V.-M.).
Blanca E López-ContrerasUnidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Rosalinda Posadas-SánchezDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (R.P.-S., C.P.-R.).
Carlos Posadas-RomeroDepartamento de Endocrinología, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (R.P.-S., C.P.-R.).
Sandra Romero-HidalgoDepartamento de Genómica Computacional, INMEGEN, Mexico City (S.R.-H.).
Sofía Morán-RamosUnidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Mayra Domínguez-PérezLaboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City (L.J.-A., M.D.-P., T.V.-M.).
Marisol Olivares-ArevaloUnidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Priscilla López-MontoyaUnidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Roberto Nieto-GuerraUnidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
Víctor Acuña-AlonzoEscuela Nacional de Antropología e Historia, Mexico City (V.A.-A., G.M.-P.).
Gastón Macín-PérezEscuela Nacional de Antropología e Historia, Mexico City (V.A.-A., G.M.-P.).
Rodrigo Barquera-LozanoMax Planck Institute for the Science of Human History, Jena, Germany (R.B.-L.).
Blanca E Del-Río-NavarroHospital Infantil de México Federico Gómez, Mexico City (B.E.D.-R.-N.).
Israel González-GonzálezHospital General Rubén Leñero, Mexico City (I.G.-G., F.C.-P.).
Francisco Campos-PérezHospital General Rubén Leñero, Mexico City (I.G.-G., F.C.-P.).
Francisco Gómez-PérezUnidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (F.G.-P., C.A.A.-S.).
Victor J ValdésInstituto de Fisiología Celular, UNAM, Mexico City (V.J.V., A.S., L.V.).
Alicia SampieriInstituto de Fisiología Celular, UNAM, Mexico City (V.J.V., A.S., L.V.).
Juan G Reyes-GarcíaSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City (J.G.R.-G., F.J.F.-M.).
Miriam Del C Carrasco-PortugalUnidad de Investigación en Farmacología, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City (M.C.-P., F.J.F.-M.).
Francisco J Flores-MurrietaSección de Estudios de Posgrado e Investigación, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City (J.G.R.-G., F.J.F.-M.).
Carlos A Aguilar-SalinasUnidad de Investigación en Enfermedades Metabólicas and Departamento de Endocrinología y Metabolismo, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City (F.G.-P., C.A.A.-S.).
Gilberto Vargas-AlarcónDepartamento de Biología Molecular, Instituto Nacional de Cardiología Ignacio Chávez, Mexico City (G.V.-A.).
Diana ShihDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (D.S., A.J.L., A.H.-V.).
Peter J MeikleHead Metabolomics Laboratory, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia (P.J.M.).
Anna C CalkinBaker Heart and Diabetes Institute, Melbourne, VIC, Australia (A.C.C., B.G.D.).
Brian G DrewBaker Heart and Diabetes Institute, Melbourne, VIC, Australia (A.C.C., B.G.D.).
Luis VacaInstituto de Fisiología Celular, UNAM, Mexico City (V.J.V., A.S., L.V.).
Aldons J LusisDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (D.S., A.J.L., A.H.-V.).
Adriana Huertas-VazquezDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (D.S., A.J.L., A.H.-V.).
Teresa Villarreal-MolinaLaboratorio de Enfermedades Cardiovasculares, INMEGEN, Mexico City (L.J.-A., M.D.-P., T.V.-M.).
Samuel Canizales-QuinterosUnidad de Genómica de Poblaciones Aplicada a la Salud, Facultad de Química, Universidad Nacional Autónoma de México (UNAM)/Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City (P.L.-M., H.V.-R., L.R.M.-K., B.E.L.-C., S.M.-R., M.O.-A., P.L.-M., R.N.-G., S.C.-Q.).
National Institute of Genomic Medicine · MXInstituto Nacional de Cardiología · MXBaker Heart and Diabetes Institute · AUCentro de Investigación en Red en Enfermedades Cardiovasculares · ESUniversity of California, Los Angeles · USHospital General de México · MXInstituto Nacional de Cardiologia · BRInstituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXInstituto Nacional de Enfermedades Respiratorias · MXNational Institute of Anthropology and History · MXConsejo Nacional de Ciencia y Tecnología · GTHospital Infantil de México Federico Gómez · MXInstituto Politécnico Nacional · MXMax Planck Institute for the Science of Human History · DE

Funding

Systems Genetics Dissection of Non-alcoholic SteatohepatitisR01DK117850 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Aldons Jake Lusis · 2019 to 2026
$4.6M
Systems genetics approach to inflammatory mechanisms in atherosclerosisR01HL147883 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE · 2019 to 2022
$3.0M
Gut microbiota and metabolite interactions in atherosclerosisR01HL144651 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LUSIS, ALDONS JAKE, REY, FEDERICO E · 2019 to 2022
$2.6M
NHLBI NIH HHS R01 HL144651NHLBI NIH HHS R01 HL147883NIDDK NIH HHS R01 DK117850
6 · The paper itself

Abstract

Objective: Low HDL-C (high-density lipoprotein cholesterol) is the most frequent dyslipidemia in Mexicans, but few studies have examined the underlying genetic basis. Our purpose was to identify genetic variants associated with HDL-C levels and cardiovascular risk in the Mexican population. Approach and Results: A genome-wide association studies for HDL-C levels in 2335 Mexicans, identified four loci associated with genome-wide significance: CETP, ABCA1, LIPC, and SIDT2. The SIDT2 missense Val636Ile variant was associated with HDL-C levels and was replicated in 3 independent cohorts (P=5.9×10−18 in the conjoint analysis). The SIDT2/Val636Ile variant is more frequent in Native American and derived populations than in other ethnic groups. This variant was also associated with increased ApoA1 and glycerophospholipid serum levels, decreased LDL-C (low-density lipoprotein cholesterol) and ApoB levels, and a lower risk of premature CAD. Because SIDT2 was previously identified as a protein involved in sterol transport, we tested whether the SIDT2/Ile636 protein affected this function using an in vitro site-directed mutagenesis approach. The SIDT2/Ile636 protein showed increased uptake of the cholesterol analog dehydroergosterol, suggesting this variant affects function. Finally, liver transcriptome data from humans and the Hybrid Mouse Diversity Panel are consistent with the involvement of SIDT2 in lipid and lipoprotein metabolism. Conclusions: This is the first genome-wide association study for HDL-C levels seeking associations with coronary artery disease in the Mexican population. Our findings provide new insight into the genetic architecture of HDL-C and highlight SIDT2 as a new player in cholesterol and lipoprotein metabolism in humans.

Indexed as

Polymorphism, Single NucleotideAdultAge of OnsetAnimalsBiomarkersCase-Control StudiesChildCholesterol, HDLCoronary Artery DiseaseDisease Models, AnimalFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHeart Disease Risk FactorsHEK293 CellsHumansBiomarkersCholesterol, HDLNucleotide Transport ProteinsSIDT2 protein, humanSidt2 protein, mousecholesterolcoronary artery diseasedyslipidemiasgeneticsgenome

Identifiers

PMID34233476
PMCPMC8664085
OpenAlexW3181189525

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.